Back to results
US 2010/0137392 A1Published application
Therapy for the treatment of disease
AssigneeTheravida, Inc.
InventorMehdi PABORJI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions comprising oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.
Claims19
A method of treating overactive bladder in a patient comprising
- administering to a patient in need thereof a therapeutically effective amount of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
- wherein the oxybutynin and pilocarpine are administered such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for tolterodine;
- whereby a symptom of overactive bladder is alleviated or ameliorated.
A method of treating overactive bladder in a patient comprising
- administering to a patient in need thereof oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, in a dose in the range of between 1 mg to 30 mg, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, in a dose in the range of between 1 mg to 30 mg,
- wherein the oxybutynin and pilocarpine are administered such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for tolterodine;
- whereby a symptom of overactive bladder is alleviated or ameliorated.
A method of treating overactive bladder in a patient comprising
- administering to a patient in need thereof 5 mg of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and 5 mg of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
- wherein the oxybutynin and pilocarpine are administered such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for tolterodine;
- whereby a symptom of overactive bladder is alleviated or ameliorated.
Dependencies are inferred from the claim text.